Summit Therapeutics Inc.

NasdaqGM:SMMT Stock Report

Market Cap: US$14.7b

Summit Therapeutics Management

Management criteria checks 2/4

Summit Therapeutics' CEO is Bob Duggan, appointed in Jul 2022, has a tenure of 2.33 years. directly owns 74.81% of the company’s shares, worth $11.03B. The average tenure of the management team and the board of directors is 2.3 years and 4.5 years respectively.

Key information

Bob Duggan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.3yrs
CEO ownership74.8%
Management average tenure2.3yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics May Have Further Upside From Here

Aug 03

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

May 06

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

CEO

Bob Duggan (80 yo)

2.3yrs

Tenure

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Duggan
Co-CEO & Executive Chairman2.3yrsno data74.81%
$ 11.0b
Mahkam Zanganeh
Co-CEO, President & Director2.3yrsUS$20.56m4.85%
$ 714.8m
Manmeet Soni
COO, CFO & Director1.1yrsUS$23.97m0.41%
$ 60.4m
Dame Davies
Co-Founderno datano datano data
Bhaskar Anand
Chief Accounting Officer & Head of Financeless than a yearno data0.018%
$ 2.6m
Abby Murphy
Head of Human Resources1.6yrsno datano data
Divya Chari
Head of Global Clinical Operations4.7yrsno datano data
Dave Gancarz
Chief Business & Strategy Officerno datano datano data
Betty Chang
Head of Research3.4yrsno datano data
Fong Clow
Chief Biometrics Officer3.8yrsno datano data
Shelley Spray
Chief Education & Brand Officer1.8yrsno datano data
Juthamas Sukbuntherng
Head of Clinical Pharmacology & DMPK3.3yrsno datano data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: SMMT's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Duggan
Co-CEO & Executive Chairman4.9yrsno data74.81%
$ 11.0b
Mahkam Zanganeh
Co-CEO, President & Director4yrsUS$20.56m4.85%
$ 714.8m
Manmeet Soni
COO, CFO & Director4.9yrsUS$23.97m0.41%
$ 60.4m
Dame Davies
Co-Founderno datano datano data
Kenneth Clark
Lead Independent Director3.1yrsUS$334.65kno data
Marcel van den Heuvel
Member of Scientific Advisory Boardno datano datano data
Francesco Muntoni
Member of Scientific Advisory Boardno datano datano data
Roger Patient
Member of Scientific Advisory Boardno datano datano data
Edith Sim
Member of Scientific Advisory boardno datano datano data
Bob Sim
Member of Scientific Advisory boardno datano datano data
Derek Stemple
Member of Scientific Advisory boardno datano datano data
Jean-Paul Vincent
Member of Scientific Advisory boardno datano datano data

4.5yrs

Average Tenure

65yo

Average Age

Experienced Board: SMMT's board of directors are considered experienced (4.5 years average tenure).